ライフサイエンスコーパス: radiocontrast

1 lling for comorbidity and acuity of illness, radiocontrast administration associated with an odds rat

2 to estimate the risk of AKI associated with radiocontrast administration within each stratum.

3 We infused the radiocontrast agent into the pancreatic ducts of wild-ty

4 exposed mouse and human acinar cells to the radiocontrast agent iohexol (Omnipaque; GE Healthcare, P

5 (10.0 mg/kg), vehicle or antagonist, and the radiocontrast agent lopamidol (2,9 g iodine/kg).

6 bitor FK506 before and after infusion of the radiocontrast agent.

7 ria, proven DHR mainly included reactions to radiocontrast agents (n = 2) and ibuprofen (n = 1).

8 Radiocontrast agents are required for radiographic proce

9 Radiocontrast agents cause pancreatic inflammation in mi

10 ed whether exposure of pancreatic tissues to radiocontrast agents during endoscopic retrograde cholan

11 dynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia.

12 t," "contrast medium," "contrast media," or "radiocontrast" and any of the words or phrases "nephroto

13 cr after the administration of intravascular radiocontrast are associated with adverse patient outcom

14 we created multiple estimates of the risk of radiocontrast-associated nephropathy among adult patient

15 In conclusion, the risk of radiocontrast-associated nephropathy may be overstated i

16 Estimates of the incidence of radiocontrast-associated nephropathy vary widely and suf

17 actice because of an aversion to the risk of radiocontrast-associated nephrotoxicity ("renalism") is

18 The perceived risk of radiocontrast-associated nephrotoxicity may influence th

19 In general, patients who received radiocontrast did not develop AKI at a clinically signif

20 e, prostaglandin inhibitors, cyclosporine A, radiocontrast dyes and volatile anesthetic agents.

21 rdiopulmonary bypass, minimizing injury from radiocontrast dyes or other nephrotoxic agents, and opti

22 empting to balance the potential benefits of radiocontrast-enhanced imaging and the risk of AKI.

23 Radiocontrast has long been thought of as nephrotoxic; h

24 The drug has actions relevant to radiocontrast-induced nephropathy (RCIN) that include va

25 A role for endothelin in the pathogenesis of radiocontrast-induced nephropathy has been suggested by

26 oral N-acetylcysteine for the prevention of radiocontrast-induced nephropathy have yielded inconsist

27 othelin-A receptor antagonist BMS-182,874 in radiocontrast-induced nephropathy in rats.

28 ced the marked diuresis and mTAL necrosis in radiocontrast-induced nephropathy in rats.

29 Radiocontrast-induced nephropathy was produced in anesth

30 unction and structure in this acute model of radiocontrast-induced nephropathy.

31 mmediate hypersensitivity reactions (IHR) to radiocontrast media (RCM).

32 ced kidney function before administration of radiocontrast media (RCM).

33 molar contrast material to prevent recurrent radiocontrast media anaphylaxis.

34 ion from acute renal failure associated with radiocontrast media treatment.

35 ich carry a negative charge similar to ionic radiocontrast media, the major cause of iatrogenic anaph

36 perative drugs, heparins, platinum salts and radiocontrast media.

37 with renal insufficiency who are to receive radiocontrast media.

38 For patients, even in uncomplicated cases of radiocontrast medium infusion during cardiac catheteriza

39 onic sodium bicarbonate infusions to prevent radiocontrast medium-induced renal failure.

40 fy its use for a group of patients receiving radiocontrast medium.

41 ence of a universally accepted definition of radiocontrast nephropathy (RCN) has hampered efforts to

42 rch on N-acetylcysteine and the incidence of radiocontrast nephropathy is too inconsistent at present

43 s likely relates to increased medication and radiocontrast use, enhanced diagnosis, and coding change

44 the complex survey design, patients to whom radiocontrast was and was not administered developed AKI